WO2023203378 - TREATMENT OF BRAIN COPPER DISORDERS
National phase entry:
Publication Number
WO/2023/203378
Publication Date
26.10.2023
International Application No.
PCT/IB2023/000203
International Filing Date
19.04.2023
Title **
[English]
TREATMENT OF BRAIN COPPER DISORDERS
[French]
TRAITEMENT DE TROUBLES LIÉS AU CUIVRE DU CERVEAU
Applicants **
PHILBERT, Sasha, A.
PHILERA NEW ZEALAND LTD.
Inventors
COOPER, Garth
Priority Data
63/332,551
19.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2629 | |
| EPO | Filing, Examination, Granting | 13630 | |
| Japan | Filing, Examination, Granting | 2399 | |
| South Korea | Filing, Examination, Granting | 2573 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
26,571
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to the treatment and prevention of impaired cognitive function, cognitive decline and/or dementia or signs of cerebral neurodegeneration in a subject with diabetes mellitus by administration of a pharmaceutical composition comprising a compound capable of lowering the level or amount of copper in the hippocampus, or elsewhere in the brain, of the subject.[French]
La présente invention concerne le traitement et la prévention de la fonction cognitive altérée, du déclin cognitif et/ou de la démence ou des signes de neurodégénérescence cérébrale chez un sujet atteint de diabète sucré par l'administration d'une composition pharmaceutique comprenant un composé capable d'abaisser le niveau ou la quantité de cuivre dans l'hippocampe, ou ailleurs dans le cerveau, du sujet.